Institute for Clinical & Economic Review Releases Draft Evidence Report on Obeticholic Acid for Nonalcoholic Steatohepatitis
March 20, 2020
March 20, 2020
BOSTON, Massachusetts, March 20 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals, Inc.) for the treatment of nonalcoholic steatohepatitis (NASH). This preliminary draft marks the midpoint of ICER's process of assessing these treatments, and the findings . . .
The Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals, Inc.) for the treatment of nonalcoholic steatohepatitis (NASH). This preliminary draft marks the midpoint of ICER's process of assessing these treatments, and the findings . . .